The data is conclusive, DCTs provide better returns on investment than traditional trials.
In fact, new analysis by Tufts CSDD shows DCTs can provide up to:
Through reductions in clinical trial cycle time, screen failure reductions, and more.
Learn more with your free copy of the analysis.
Tufts CSDD is an independent, academic, non-profit research center at Tufts University in Boston. Founded in 1976, the university is, dedicated to researching drug development.
